FUNDAMENTALS · Fundamentals · TW Healthcare

ICARES Medicus (6612) Fundamentals 2026 — P/E 79.7x, Revenue Analysis | SniperIQ

ICARES Medicus (6612) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT

.4B, trading at NT$70.90 on the TWO. This SniperIQ fundamentals page covers ICARES Medicus's valuation (P/E 79.7x, P/B 1.1x), profitability (net margin -0.5%), revenue (NT
.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
.4B
P/E (TTM)79.7x
Net Margin-0.5%
Revenue (FY25)NT
.1B

Full research coverage

Frequently Asked Questions

What is ICARES Medicus's market cap?

ICARES Medicus (6612) has a market capitalization of approximately NT

.4B, trading at NT$70.90 on the TWO. Market cap moves with the live share price.

What is ICARES Medicus's P/E ratio?

ICARES Medicus's trailing twelve-month P/E ratio is 79.7x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is ICARES Medicus?

ICARES Medicus runs a net profit margin of -0.5%, a gross margin of 58.5%, and an operating margin of 9.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does ICARES Medicus generate?

ICARES Medicus reported revenue of NT

.1B for fiscal year 2025, with net income of NT
M and earnings per share (EPS) of 1.09. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does ICARES Medicus pay a dividend?

ICARES Medicus offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is ICARES Medicus financially healthy?

ICARES Medicus carries a debt-to-equity ratio of 0.45x and a current ratio of 2.07x, with a market beta of 0.28. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is ICARES Medicus a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ICARES Medicus (6612) the key facts are: market cap NT

.4B, P/E 79.7x, revenue NT
.1B, 52-week range 66-110.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track ICARES Medicus's full fundamentals live

Get ICARES Medicus's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.